Information for professionals

Medical updates

Paper: “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome” By Dr. Orrin Devinsky

Summary:

In this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg or placebo, in addition to standard antiepileptic treatment. 14-week treatment period.

Results: The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo. The percentage of patients who had at least a 50% reduction in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo

Devinsky et al. N Engl J Med 2017;376:2011-20.

https://www.nejm.org/doi/10.1056/NEJMoa1611618

Paper: “A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?” By Dr. Helen Cross

Summary:

In this paper,  Dr. Helen Cross, warns about the risks of artisanal preparations, not only due to the impossibility to check the amount of CBD per flask and its stability but because of the risk of inconsistency or unknown constituents. Because of the characteristics and the elaboration of these flasks it is impossible to perform clinical studies to compare them with pharmaceutical products with GMP

1. J Helen Cross , Hannah Cock. A Perspective on Cannabinoids for Treating Epilepsy: Do They Really Change the Landscape? Neuropharmacology 2020 Jun 15;170:107861.

https://pubmed.ncbi.nlm.nih.gov/31770546/

Paper: “Cannabis and epilepsy” By Dr. Rhys H. Thomas and Dr. Mark O. Cunningham

Summary:

Review on the “state of art” of Cannabis and epilepsy, warns about the differences between pharmaceutical cannabis and artisanal preparations. Concludes by suggesting to separate ourselves from our thoughts about artisanal preparations. Cannabidiol oils rigorously tested in clinical trials.

https://pn.bmj.com/content/early/2018/10/18/practneurol-2018-002058.info?versioned=true

Research Letter: “Labeling Accuracy of Cannabidiol Extracts Sold Online” By Marcel O. Bonn-Miller, PhD; Mallory J. E. Loflin, PhD; Brian F. Thomas, PhD

Work made by researchers of UPenn in JAMA who performed a comparison between contents of commercialized products, founding great discrepancies between what was initially announced and the eventual results. The discrepancies was found both in the CBD and the THC. It outstands the importance of standardizing manufacturing processes.

https://jamanetwork.com/journals/jama/article-abstract/2661569

Paper: “Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol” “ By José A. S. Crippa, Ana C. S. Crippa, Jaime E. C. Hallak, Rocio Martín-Santos, and Antonio W. Zuardi”

Summary:

Work by Crippa and others, reporting 2 cases of THC intoxication due to artisanal preparations. It highlights the importance of access to GMP products. It also mentions the risks of using of artisanal oils in teens and children because of the known damage produced by Δ9-THC in the developing brain.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043219/

News article: “Study finds artisanal CBD not as effective as pharmaceutical CBD for reducing seizures” By Doctor Nathan T. Cohen, M.D., of Children's National Hospital in Washington D.C.

Summary:

News about the work presented in the American Academy of Neurology 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020. With regards to the difference of impact between home-made products containing CBD and pharmaceutical products. There was higher efficacy noticed in pharmaceutical products rather than in artisanal ones. “The difference in seizure control is dramatic and is definitely of concern since many people continue to use artisanal CBD”, Said lead author Cohen.

https://www.eurekalert.org/pub_releases/2020-02/aaon-sfa022420.php/

Presentation delivered by Dra. Helen Cross “Cannabinoids available and used in clinical practice and their impact on the treatment of epilepsy”

This is the talk delivered by Dr. Helen Cross, President of ILAE (International League Against Epilepsy) on the 15th of October 2020 within the 2020 LACE Congress framework.

Presentation delivered by Dr. Gabriel Martino “Convupidiol launch – LACE Congress 2020”

Convupidiol

CBD 100MG X ML

35 ML - Oral Solution

Each ml. of oral solution contains

  • Cannabidiol 100,00 mg
  • Vanilla flavor
  • Sesame oil
Download prospectus PDF

Professionals Contact

Please complete the required information. We will contact you as soon as possible.